A phase Ib study has explored the combination of durvalumab with DCC-3014 (vimseltinib), a selective inhibitor of CSF1R, in 13 patients with advanced STS (7 leiomyosarcoma, 2 UPS, 2 DDLPS, 1 synovial sarcoma and 1 liposarcoma) [112]. The gene discussed is CSF1R; the disease is synovial sarcoma.